Advertisement

 

 

Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.

Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.
Author Information (click to view)

Chung KF,


Chung KF, (click to view)

Chung KF,

Advertisement

European respiratory review : an official journal of the European Respiratory Society 2017 09 2726(145) pii 170064
Abstract

Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies – the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off – it is already here, but we need more tools and implements to carry it out for the benefit of our patients.

Submit a Comment

Your email address will not be published. Required fields are marked *

two × 5 =

[ HIDE/SHOW ]